← The Wire·Breaking·Regulation·

CAPR Investor Losses: Capricor Therapeutics Clinical Data Announcement and Corresponding 64% Stock Drop Trigger Securities Class Action for Investors

Capricor Therapeutics faces a securities-fraud class action alleging misstatements about Deramiocel and the clinical data supporting its Biologics License Application after the stock fell 64%. The filing puts regulatory-data credibility and litigation exposure at the center of the company’s next catalyst.

PR NEWSWIRE / FILE

The story

The lawsuit, announced by a securities law firm on Aug. 25, alleges that Capricor misrepresented Deramiocel and the integrity of clinical data underpinning its Biologics License Application. The allegations follow a 64% decline in Capricor's stock.

The named issues connect the company's valuation to both Deramiocel's clinical evidence and the regulatory submission built on that evidence. The litigation also creates a second channel of scrutiny beyond the underlying drug program.

Next, the docket, Capricor's response, and any regulatory developments will determine whether the allegations broaden the existing uncertainty around the application.

Our read · Tue, Aug 25

The securities-fraud filing moves the risk to the downside for CAPR by pairing Deramiocel data scrutiny with fresh litigation exposure.

Why. The immediate consequence is a higher uncertainty premium around both the Deramiocel application and the credibility of the supporting clinical data. The 64% stock drop is already part of the record, so without a dated forward catalyst or enrichment on valuation, positioning, and the lawsuit’s merits, the evidence supports a downside risk read but not a quantified new trade.

Both cases

The case it holdsCapricor could contain the damage if its response and subsequent regulatory handling preserve confidence in Deramiocel and the Biologics License Application.
The case it breaksThe bear case is stronger on the available facts: allegations over data integrity, combined with a 64% stock drop and new securities litigation, leave the program exposed to further credibility and regulatory pressure.

What could change this view: A company response, court dismissal, or regulatory confirmation that the application and clinical data remain intact would undercut the litigation-driven downside case.

Capr stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Keep reading

More on CAPR

Capricor reports 76% slower upper-limb decline after deramiocel switch

Latest on the Wire

AMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions rise
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by PR Newswire, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →